Hypophosphatemic Rickets X-linked Dominant
📧 Sign up to get email alerts when something new happens for Hypophosphatemic Rickets X-linked Dominant.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-10EMA Authorised: Crysvita (burosumab) — Kyowa Kirin Holdings B.V.
EU authorization for Crysvita (burosumab) for familial hypophosphatemia, X-linked dominant hypophosphatemic rickets, and osteomalacia, grant…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Calcitriol Monotherapy for X-Linked Hypophosphatemia [EARLY_Phase 1]
The document reports an EARLY_PHASE1 trial of Calcitriol as monotherapy for X-linked hypophosphatemia with status ACTIVE_NOT_RECRUITING.